not appear to predict response in this group. There were no adverse events reported.

Conclusion: Yttrium therapy is not widely used with only one unit in Northern Ireland performing the procedure. The use of effective DMARDs and biological therapy has improved management of psoriatic and rheumatoid arthritis. In spite of this some patients still have refractory disease. We have shown in this observational study that in patients with knee synovitis despite treatment with DMARDs, biologics and intra-articular steroids, Yttrium synovectomy shows good efficacy, is a relatively low cost and generally safe treatment option for these patients.

Going forward this study and our standard operating procedure will allow us to develop criteria to help select patients for Yttrium therapy and standardize our treatment.

REFERENCES:

Disclosure of Interests: None declared

FRIO443 IMPACT OF APREMILAST ON PSAID CORE COMPONENTS IN PATIENTS WITH A LIMITED NUMBER OF ACTIVE JOINTS: RESULTS FROM THE REAL-WORLD, PROSPECTIVE, MULTICENTRE REWARD STUDY

Tim Jansen1, Eric-Jan Kroot2, Arie van Vliet3, Jan Pander2, Marijn Vis4, Vicuiri MC, Venlo, Netherlands; 2Elkerleik, Helmond, Netherlands; 3Celgene, Utrecht, Netherlands; 4ErasmusMC, Rotterdam, Netherlands

Background: Recent data suggest that patients with moderately active psoriatic arthritis (PsA) and a limited number of active joints have a high likelihood of achieving treatment goals with apremilast treatment.1,2 Real-world evidence on the effect of apremilast on patients with PsA is scarce.

Objectives: To describe the effects of apremilast on the impact of disease in real-world patients with PsA.

Methods: The prospective, multicentre, observational REWARD study (The Netherlands) is investigating apremilast treatment in real-world patients with PsA. Descriptive statistics were assessed for disease measures, including swollen joint count (SJC; 0-66) and tender joint count (TJC; 0-68), PsAID (0-10) and patient perception of the impact of their disease is limited.

Results: A total of 48 patients from 9 clinics who were receiving apremilast were included in this interim analysis. Among these patients, 31 (65%) had SJC ≤4 and 17 (35%) had SJC >4 at baseline. Patients with SJC ≤4 at baseline, 18 and 8 had at least 3 and 6 months of follow-up, respectively. At the end of the follow-up period (median: 15 months), patients with SJC ≤4 included a mean age of 54 years, mean BMI of 29.1 and mean years since PsA diagnosis of 7.0 years; 58% of patients were female, 90% had prior csDMARD use and 29% had prior biologic use. For patients with SJC ≤4, disease measures were as follows: The mean SJC at baseline, 3 and 6 months were 1.1, 0.6 and 0.1 and the mean TJC at baseline, 3 and 6 months were 4.5, 3.6 and 1.5. The mean PsAID scores at baseline, 3 and 6 months were 4.2, 3.4 and 2.6. Individual PsAID domain scores by time points are shown (Figure). Patients with a limited number of swollen joints showed gradual improvements in all domains of the PsAID. Mean Pain VAS scores at baseline, 2 weeks, 6 weeks, 3 months and 6 months were 47, 48, 39, 29 and 26 in these patients.

Conclusion: Results from the real-world, prospective, multicentre, observational REWARD study suggest that PsA patients with a limited number of active swollen joints may benefit from apremilast treatment. Apremilast was associated with improvements in the perceived impact of disease, as observed by reductions in the PsAID and its core components.

REFERENCES:

Disclosure of Interests: Tim Jansen Grant/research support from: Olteo, Consultant for: Abbvie, Celgene, Menarini, Novartis, Speakers bureau; Grünenthal, Eric-Jan Kroot: None declared, Arie van Vliet Employee of: Celgene Corporation, Jan Pander Employee of: Celgene Corporation, Marijn Vis Grant/research support from: Novartis

FRIO444 EFFICACY AND SAFETY OF SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS FOLLOWING INADEQUATE RESPONSE TO SYNTHETIC OR BIOLOGICAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN REAL-LIFE SETTINGS

Kalilopi Kladianou1, Anrygo Lazarini1, Dimitrios Tseronis2, Christina Tsalapaki1, Panagiota Rapsomanikis2, Katerina Antonatou1, Konstantinos Thomas1, Dimitrios Bourpas1, Dimitrios Vassilopoulos1, KATSIMPIRI PELAGIA1, Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine-Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine, Athens, Greece, 2Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine-Clinical Immunology-Rheumatology Unit, 4th Department of Medicine, Athens, Greece

Background: The data regarding the efficacy and safety of Secukinumab (SEC) in patients with psoriatic arthritis (PsA) in daily clinical practice are scarce.

Objectives: To assess the safety and efficacy of SEC in patients with PsA in real life settings.

Methods: All PsA patients treated with SEC in the Rheumatology Units of 2 referral University Hospitals were prospectively included (from 3/2016-12/2018). Patients' characteristics, treatments and indices of disease activity (DAPSA, DAS28-ESR, BASDAI) and function (HAQ, BASHI) as well as the extent of skin disease (BSA) were recorded at baseline and during therapy.

Results: 79 patients treated with SEC were included; 75% were females (n=59) with a mean age of 54±13.4 years, a median disease duration of 7.8 years and a median SEC treatment duration of 10 months (IQR 13). At baseline, 42% had axial involvement, 25% enthesis and 13% dactyli, the majority of patients had previously failed anti-TNFs (91%, n=72; n=1, n=3 patients failed anti-TNFs and anti-TNFs, respectively). At the end of the follow-up period (median: 15 months), patients' disease activity (median DAPSA: 29 → 18.5, p<0.001, DAS28: 4.6 → 3.7, p=0.05, BASDAI: 5.5 → 3.2, p=0.15), function (median HAQ: 1 → 0.38, p=0.07, BASFI: 7 → 3.2, p=0.14) and skin psoriasis (median BSA: 2% → 0%, p=0.05) improved. Drug survival at the last follow-up visit was 63% (n=50). Reasons for SEC discontinuation were inadequate response (25%, n=20), serious adverse events (7%, n=5) or other reasons (5%, n=4). During follow-up there were 12 adverse events (1.2/100 patient-years); among them 5 were serious (0.5/100 patient-years). The rate of serious infections was 0.1/100 patient-years. Two fungal infections (one oral-genital and one inguinal that improved with local therapy) and one endometrial cancer was observed by reductions in the PsAID and its core components.

Conclusion: In a large, real life, cohort of patients with PsA, resistant to different biologics (anti-TNFs and/or anti-IL12/23), SEC displayed a high retention rate (63% after a median follow-up of 15 months) without significant side effects. These data emphasize the role of SEC as a viable therapeutic option even in patients with difficult to treat, multiresistant PsA in daily clinical practice.

Acknowledgement: This work was supported by research grants from the Special Account for Research Grants (S.A.R.G.), National and Kapodistrian University of Athens, Athens, Greece

Disclosure of Interests: None declared